D. P. Dearnaley, M. R. Sydes, J. D. Graham, E. G. Aird, D. Bottomley, R. A. Cowan, R. A. Huddart, C. C. Jose, J. H. Matthews, J. Millar, A. R. Moore, R. C. Morgan, J. M. Russell, C. D. Scrase, R. J. Stephens, I. Syndikus, M. K. Parmar and RT01 Collaborators “Escalated-Dose versus Standard-Dose Conformal Radiotherapy in Prostate Cancer: First Results from the MRC RT01 Randomised Controlled Trial,” The Lancet Oncology, Vol. 8, No. 6, 2007, pp. 475-487. http://dx.doi.org/10.1016/S1470-2045(07)70143-2

has been cited by the following article:

• TITLE: Predictability and Management of OARs Toxicity in Patients with Prostate Cancer Treated with High-Dose Radiotherapy

  AUTHORS: Vincenzo Ravo, Domenico Borrelli, Sara Falivene, Rossella Di Franco, Matteo Muto, Angela Argenone, Valentina Borzillo, Fabrizio Cammarota, Paolo Muto

  KEYWORDS: Toxicity; Radiotherapy; Prostate Cancer; Prevention

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.10, December 13, 2013

  ABSTRACT: Aim: To evaluate the predictability of toxicity analyzing the dose-volume histograms (DVHs) and to verify the effectiveness of preventive measures limiting side toxicity considering the evolution of the radiation techniques for prostate cancer treatment. Materials and Methods: 208 patients with localized prostate cancer were treated with exclusive radiotherapy until 73.8 Gy (group A) or 79.2 Gy (group B) with the dose escalation technique. Preventive measures to minimize the side effects were recommended in group B. Results: The assessment of genitourinary toxicity was similar while gastrointestinal toxicity was better in group B. Valuating the treatment plans, we found that most of the patients developing toxicity had “borderline” DVHs. Conclusion: Our analysis led to the establishment of a protocol for the management of patients with “border-line” DVH.